NYSE - Delayed Quote USD

Smith & Nephew plc (SNN)

Compare
25.76 +0.08 (+0.31%)
At close: December 11 at 4:00:02 PM EST
Loading Chart for SNN
DELL
  • Previous Close 25.68
  • Open 25.50
  • Bid 25.72 x 900
  • Ask 25.76 x 1100
  • Day's Range 25.39 - 25.81
  • 52 Week Range 23.65 - 31.72
  • Volume 830,784
  • Avg. Volume 813,054
  • Market Cap (intraday) 11.231B
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) 36.80
  • EPS (TTM) 0.70
  • Earnings Date Feb 25, 2025
  • Forward Dividend & Yield 0.75 (2.91%)
  • Ex-Dividend Date Oct 4, 2024
  • 1y Target Est 32.55

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

www.smith-nephew.com

18,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SNN

View More

Performance Overview: SNN

Trailing total returns as of 12/12/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SNN
2.89%
FTSE 100
7.50%

1-Year Return

SNN
0.84%
FTSE 100
10.18%

3-Year Return

SNN
14.03%
FTSE 100
14.01%

5-Year Return

SNN
34.85%
FTSE 100
15.20%

Compare To: SNN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SNN

View More

Valuation Measures

Annual
As of 12/11/2024
  • Market Cap

    10.96B

  • Enterprise Value

    14.05B

  • Trailing P/E

    36.91

  • Forward P/E

    11.01

  • PEG Ratio (5yr expected)

    0.43

  • Price/Sales (ttm)

    1.99

  • Price/Book (mrq)

    2.16

  • Enterprise Value/Revenue

    2.49

  • Enterprise Value/EBITDA

    14.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.41%

  • Return on Assets (ttm)

    4.51%

  • Return on Equity (ttm)

    5.84%

  • Revenue (ttm)

    5.64B

  • Net Income Avi to Common (ttm)

    305M

  • Diluted EPS (ttm)

    0.70

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    568M

  • Total Debt/Equity (mrq)

    70.22%

  • Levered Free Cash Flow (ttm)

    247.88M

Research Analysis: SNN

View More

Company Insights: SNN

Research Reports: SNN

View More

People Also Watch